Earnings Scheduled For August 11, 2022
Companies Reporting Before The Bell
• Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million.
HOOKIPA Gets FDA Nod For Initial-Stage Prostate Cancer Study
The U.S. Food and Drug Administration (FDA) has accepted HOOKIPA Pharma’s (NASDAQ: HOOK) Investigational New Drug (IND) application for HB-300, a novel arenaviral immunotherapy for the treatment of metastatic castration-resistant prostate cancer.
HOOKIPA Pharma Announces FDA Accepts Co.’s Investigational New Drug Application For HB-300 For The Treatment Of Metastatic Castration-resistant Prostate Cancer
Novel arenaviral immunotherapy is directed against the prostate cancer targets PAP and PSA; Phase 1/2 trial to commence by early 2023
Drug Master File (DMF) accepted to support future FDA submissions
HOOKIPA Pharma’s Return On Capital Employed Insights
According to data from Benzinga Pro, during Q1, HOOKIPA Pharma's (NASDAQ:HOOK) reported sales totaled $1.45 million. Despite a 15.38% increase in earnings, the company posted a loss of $17.97 million.
HOOKIPA Announced Alternating 2-vector HB-202/HB-201 Therapy Showed Superior Tumor Response With 56% of Treated Patients Showing Target Lesion Shrinkage vs 38% of HB-201 Recipients in Head and Neck Cancer Trial; Data Presented at ASCO
HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced positive Phase 1 results from its HB-200 program evaluating single-vector HB-201 and alternating 2-vector HB-202/HB-201 in advanced Human Papillomavirus 16-positive (HPV16+) head and neck cancer patients.
Recap: HOOKIPA Pharma Q1 Earnings
HOOKIPA Pharma (NASDAQ:HOOK) reported its Q1 earnings results on Monday, May 16, 2022 at 07:00 AM.
Here's what investors need to know about the announcement.
Earnings Scheduled For May 16, 2022
Companies Reporting Before The Bell
• AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand.
Hookipa Shares Jump On New Preclinical Data On Cancer Immunotherapies
HOOKIPA Pharma Inc (NASDAQ: HOOK) has
HOOKIPA Highlights Preclinical Data On Combo With Co-Stimulatory 4-1BB Agonists, Adoptive T-Cell Transfer Showed T-Cell Responses, Tumor Control
Preclinical data on combination with co-stimulatory 4-1BB agonists or adoptive T cell transfer showed potent T cell responses and significant tumor control
Preclinical data also expand evidence on
